Water-Soluble UDCA Prodrugs via Phosphate Ester Linkages
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current UDCA prodrugs face challenges in aqueous solubility and stability, which hinders their effectiveness in clinical applications, particularly in rapid treatment of conditions like stroke or myocardial infarction, and their synthesis is complex.
Innovation Solution
Development of highly water-soluble phosphate ester and oxymethylphosphate prodrugs of UDCA, including phosphoryloxymethyl carboxylate (POMC) prodrugs, which enhance aqueous solubility and stability, and are designed for rapid bioactivation by alkaline phosphatase, facilitating their therapeutic potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If phosphate ester prodrugs are synthesized to increase aqueous solubility, then water solubility is improved by several orders of magnitude, but the molecular structure becomes more complex
Solution Approach 1:
A phosphate group is introduced as an intermediary solubilizing moiety that attaches to the UDCA molecule. This phosphate group acts as a mediator that dramatically increases water solubility through its ionic character while maintaining the parent drug's pharmacological activity after enzymatic cleavage.
Solution Approach 2:
The chemical structure of UDCA is modified by changing the physical-chemical parameters of the molecule - specifically by adding a phosphate group that alters the solubility parameter from lipophilic to hydrophilic, enabling aqueous formulation without changing the core therapeutic structure.
2Speed
If prodrugs are designed for rapid bioactivation by alkaline phosphatase, then treatment speed is improved for acute conditions, but the prodrug structure becomes more complex
Solution Approach 1:
The prodrug structure is designed to be self-activating through endogenous alkaline phosphatase enzymes present in the body. The phosphate ester linkage serves as a built-in trigger that is automatically cleaved by physiological enzymes, eliminating the need for external activation mechanisms or complex delivery systems.
3Reliability
If multiple prodrug variants are synthesized to optimize therapeutic outcomes, then treatment effectiveness is improved, but the synthesis process becomes more complex
Solution Approach 1:
The research systematically segments the UDCA molecule by modifying different functional groups (hydroxyl groups at various positions) with phosphate groups. This segmentation approach allows identification of the most effective prodrug variant while maintaining a standardized synthesis platform that can be adapted to different positions.
Solution Approach 2:
Phosphate groups are selectively introduced at specific positions on the UDCA molecule (e.g., 3-position, 7-position) rather than uniformly throughout. This local modification strategy optimizes therapeutic effectiveness at critical sites while minimizing unnecessary structural complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new prodrugs demonstrate significant cytoprotective properties, inhibiting TGFβ-induced cytotoxicity and apoptosis, with POMC prodrugs showing rapid activation and stability, potentially offering improved therapeutic outcomes for UDCA in clinical settings.
Implementation Method 1
designed for rapid bioactivation by alkaline phosphatase
Implementation Method 2
bioactivation by alkaline phosphatase
Data Source
AI summary
Ursodeoxycholic acid (UDCA) is a bile acid with demonstrated anti-apoptotic activity in both in vitro and in vivo models. Water-soluble prodrugs of UDCA for use in indications where intravenous administration of UDCA may be preferable, such as reducing damage from stroke or acute kidney injury, are disclosed. The disclosed prodrugs showed significant anti-apoptotic activity in a series of in vitro assays.